Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R Gandara, Sarah M. Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine Malboeuf, Daniel S. Lieber, Doron Lipson, Jacob Silterra, Lukas Amler, Todd Riehl, Craig A. Cummings, Priti S. Hegde, Alan Sandler, Marcus Ballinger, David FabrizioTony Mok, David S. Shames

Research output: Contribution to journalArticle

257 Scopus citations

Fingerprint Dive into the research topics of 'Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences